To build the “best pipeline in BioMarin history,” the California biotech is looking to its already approved meds as a jumping-off point.

Orthofix has ousted its CEO and other members of its C-suite after the company’s board voted unanimously to terminate their employment “for cause” following an independent investigation.

Though designed to be a help, the “MRI mode” feature on many of Abbott’s implanted neuromodulation systems may turn out to be something of a hindrance for some users.

Fresh off a vitriolic activist battle that spurred the ouster of three board members, Exelixis plans to hydrate its pipeline with artificial intelligence.

Only two months after snagging $150 million from investors to take its first G-protein-coupled receptor (GPCR) drug into the clinic, Septerna has added another $47.5 million to the pile courtesy of a licensing deal with Vertex.

CEO Nick Leschly is leading a long list of 2seventy bio employees who are heading to the exit. With rival drugs putting its approved cell therapy under pressure, the bluebird bio spinout is eliminating 176 roles and advancing fewer R&D programs internally to stretch its cash runway out to 2026.

Roche has installed “stronger gates” to ensure that drug candidates only make it into phase 3 trials if they have a high likelihood of success, CEO Thomas Schinecker has revealed.

Rome wasn’t built in a day, and neither was Rome Therapeutics, which today revealed a series B financing extension of $72 million that includes Big Pharma pillars Johnson & Johnson and Bristol Myers Squibb.

Neumora and RayzeBio are both casting a line into the market, with each seeking to raise more than $200 million in initial public offerings this fall.

Acelyrin has given its investors a nasty shock. Months after raising $540 million in a rare biotech IPO, the company has reported the failure of its lead prospect in a phase 2b/3 inflammatory disease clinical trial, causing its share price to plummet by 58% in premarket trading.